• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    3/5/21 6:03:56 AM ET
    $NNOX
    Medical Electronics
    Health Care
    Get the next $NNOX alert in real time by email
    SC 13G 1 r34212sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

    Nano-X Imaging Ltd.
    (Name of Issuer)
     
    Ordinary shares
    (Title of Class of Securities)

     

      M70700105  
      (CUSIP Number)  
     
    December 31, 2020
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      o Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 5 pages 
     

     

    CUSIP No.  M70700105
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    YOZMA GROUP KOREA Co., Ltd.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Republic of Korea

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    2,512,000

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    2,512,000

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,512,000 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.42%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

    (1) Consists of 887,000 ordinary shares held by Yozma Global AI Fund No.2 (“Yozma Fund No.2”), (b) 1,625,000 ordinary shares held by Yozma Global AI Fund No.3 (“Yozma Fund No.3”). Yozma Group Korea is the general partner of each of Yozma Fund No.2 and Yozma Fund No.3. Wonjae Lee is the Chief Executive Officer and controlling shareholder of Yozma Group Korea and is deemed to have voting and dispositive power over the shares held by Yozma Fund No.2 and Yozma Fund No.3

     

     Page 2 of 5 pages 
     

     

    Item 1(a). Name of Issuer:
       
       NANO-X IMAGING LTD (the "Issuer")
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
       COMMUNICATIONS CENTER, NEVE ILAN, ISRAEL 9085000
       
    Item 2(a). Name of Person Filing:
       
       YOZMA GROUP KOREA Co., Ltd.
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       7F Building #2, 20, Pangyo-ro 289beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
       
    Item 2(c). Citizenship:
       
       Republic of Korea
       
    Item 2(d). Title of Class of Securities:
       
       Ordinary shares
       
    Item 2(e). CUSIP Number:  M70700105
       
    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable.

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
                      (a) Amount Beneficially Owned: See Item 9 of the cover page.
       (b) Percent of Class: See Item 11 of the cover page.
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote: See Item 5 of the cover page.
          (ii) shared power to vote or to direct the vote: See Item 6 of the cover page.
          (iii) sole power to dispose or to direct the disposition of: See Item 7 of the cover page.
          (iv) shared power to dispose or to direct the disposition of: See Item 8 of the cover page.

     

     Page 3 of 5 pages 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       Not applicable.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

     

     Page 4 of 5 pages 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      March 05, 2021  
      Date  
         
      /s/ Wonjae Lee  
      Signature  
         
      Wonjae Lee, CEO  
      Name/Title  

     

     

    Page 5 of 5 pages

     

     

    Get the next $NNOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NNOX

    DatePrice TargetRatingAnalyst
    1/6/2025$23.00Buy
    D. Boral Capital
    9/8/2023$14.50Buy
    Alliance Global Partners
    1/5/2023$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NNOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nanox to Report First Quarter 2025 Financial Results on May 22, 2025

      PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be

      5/8/25 4:03:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X

      First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indicationsEnhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play' installation processSystem design enables software upgrades and new capabilities to be added remotely following future regulatory clearances PETACH TIKVA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Nanox.ARC X

      4/17/25 8:30:54 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe

      ADOPT Study Findings Highlight Nanox.AI's Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd will present new data from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study at four major upcoming medical conferences spanning March through June 2025. The ADOPT study concluded in February 2025 and evaluated HealthVCF at four National Health Services (NHS) trusts: Cambridge, Bradford, Cardiff and

      3/26/25 7:00:13 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Financials

    Live finance-specific insights

    See more
    • Nanox to Report First Quarter 2025 Financial Results on May 22, 2025

      PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be

      5/8/25 4:03:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conferenc

      3/17/25 4:05:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update

      Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the third quarter of 2024, compared to $2.5 million in the third quarter of 2023

      11/21/24 8:00:00 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Leadership Updates

    Live Leadership Updates

    See more

    $NNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Nanox Announces Appointment of Medical Executive Moshe Shtengel as Chief Business Officer

      NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we

      5/3/21 8:00:00 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

      SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

      3/7/24 12:29:51 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G filed by NANO-X IMAGING LTD

      SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)

      2/6/24 9:36:34 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

      SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

      2/14/23 4:15:16 PM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Nano-X Imaging with a new price target

      D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00

      1/6/25 9:02:00 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Alliance Global Partners initiated coverage on Nano-X Imaging with a new price target

      Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50

      9/8/23 9:14:06 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Cantor Fitzgerald initiated coverage on Nano-X Imaging with a new price target

      Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00

      1/5/23 7:46:34 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    SEC Filings

    See more
    • SEC Form 6-K filed by NANO-X IMAGING LTD

      6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

      4/17/25 8:40:02 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form 20-F filed by NANO-X IMAGING LTD

      20-F - Nano-X Imaging Ltd. (0001795251) (Filer)

      4/9/25 4:29:36 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by NANO-X IMAGING LTD

      6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

      3/31/25 8:37:25 AM ET
      $NNOX
      Medical Electronics
      Health Care